TABLE 2.

Multivariable predictors of early trial termination or early trial termination due to poor accrual

Trial characteristic	Odds Ratio (95% confidence interval)	p‐Value
Predictors of early trial termination for any reason (n = 8687)
Cancer category
Hematologic cancer	Reference	Reference
Solid tumor	0.96 (0.85–1.08)	0.46
CNS tumor	0.84 (0.66–1.08)	0.17
Multiple histology	0.70 (0.54–0.91)	0.007
Phase
Phase 1	Reference	Reference
Phase 2	1.27 (1.14–1.41)	<0.001
Phase 3	1.05 (0.85–1.30)	0.62
Phase 4	1.24 (0.77–2.01)	0.38
Funding source
Industry	Reference	Reference
Government	0.89 (0.72–1.10)	0.27
Other	1.19 (1.02–1.38)	0.03
Multiple	0.96 (0.84–1.10)	0.55
Trial location
US only	Reference	Reference
US plus international site	0.65 (0.55–0.76)	<0.001
Predictors of early trial termination for poor accrual (n = 1975)
Phase
Phase 1	Reference	Reference
Phase 2	1.58 (1.29–1.94)	<0.001
Phase 3	1.39 (0.90–2.15)	0.13
Phase 4	2.41 (0.99–5.91)	0.05
Funding source
Industry	Reference	Reference
Government	2.68 (1.77–4.07)	<0.001
Other	4.56 (3.41–6.08)	<0.001
Multiple	3.87 (2.96–5.08)	<0.001
Therapeutic intent
Anticancer	Reference	Reference
Supportive care	1.71 (1.13–2.60)	0.011